Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Adv Anat Pathol ; 30(3): 160-166, 2023 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-36221221

RESUMO

Immune-checkpoint-inhibitor (ICI) therapy has been one of the major advances in the treatment of a variety of advanced or metastatic tumors in recent years. Therefore, ICI-therapy is already approved in first-line therapy for multiple tumors, either as monotherapy or as combination therapy. However, there are relevant differences in approval among different tumor entities, especially with respect to PD-L1 testing. Different response to ICI-therapy has been observed in the pivotal trials, so PD-L1 diagnostic testing is used for patient selection. In addition to PD-L1 testing of tumor tissue, liquid biopsy provides a noninvasive way to monitor disease in cancer patients and identify those who would benefit most from ICI-therapy. This overview focuses on the use of ICI-therapy and how it relates to common and potential future biomarkers for patient-directed treatment planning.


Assuntos
Antineoplásicos Imunológicos , Neoplasias , Oncologistas , Humanos , Antígeno B7-H1 , Patologistas , Antineoplásicos Imunológicos/uso terapêutico , Antineoplásicos Imunológicos/farmacologia , Neoplasias/tratamento farmacológico , Neoplasias/patologia , Biomarcadores Tumorais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...